Business Context and Reporting Period
This Form 8-K reports on the 2021 Annual Meeting of Stockholders held by Aclaris Therapeutics, Inc. on June 3, 2021. The filing details the voting results for four proposals submitted to security holders.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is a corporate governance report regarding stockholder voting outcomes.
Material Changes
The filing reports the successful election of three directors and the approval of executive compensation and auditor ratification. There are no material changes to financial operations or business strategy disclosed in this specific document.
Guidance, Outlook, and Voting Results
Of the 52,081,729 shares outstanding, 45,905,340 shares (88.14%) were present or represented by proxy. The voting results were as follows:
- Proposal 1 (Election of Directors): All three nominees (Christopher Molineaux, Bryan Reasons, Vincent Milano) were elected.
- Proposal 2 (Executive Compensation): Advisory approval was granted with 34,972,371 votes for, 1,308,885 against, and 6,454 abstentions.
- Proposal 3 (Compensation Vote Frequency): Stockholders voted to hold advisory votes on executive compensation every 1 year (36,262,560 votes).
- Proposal 4 (Auditor Ratification): PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm with 45,901,753 votes for.
Investor Verification Checklist
- Verify the definitive proxy statement filed on April 22, 2021, for detailed biographies of the elected directors and executive compensation specifics.
- Confirm the total number of shares outstanding and the record date used for the 88.14% participation rate.
- Review the Company's subsequent filings for the 2021 fiscal year-end financial results, as this 8-K does not contain them.